Axa S.A. Rigel Pharmaceuticals Inc Transaction History

Axa S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$1.63 - $2.62 $92,747 - $149,078	-56,900 Closed	0 $0
Q2 2019 Aug 13, 2019	SELL	$2.02 - $2.61 $69,892 - $90,306	-34,600 Reduced 37.81%	56,900 $149,000
Q4 2018 Feb 13, 2019	SELL	$2.08 - $3.36 $58,448 - $94,416	-28,100 Reduced 23.49%	91,500 $210,000
Q2 2018 Aug 13, 2018	BUY	$2.83 - $4.11 $338,468 - $491,556	119,600 New	119,600 $338,000
Q1 2018 May 14, 2018	SELL	$3.54 - $4.54 $118,236 - $151,636	-33,400 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$3.23 - $4.3 $37,145 - $49,450	-11,500 Reduced 25.61%	33,400 $130,000
Q3 2017 Nov 13, 2017	BUY	$2.18 - $2.57 $97,882 - $115,393	44,900	44,900 $114,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $4.82B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.